Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease

No abstract is available for this paper.

• Publication year

  2001

• Venue

  NeuroReport

• Publication date

  2001-07-20

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/00001756-200107200-00017PMID 11447320
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of systemic 3-nitropropionic acid-induced lesions of the dorsal striatum on cannabinoid and µ-opioid receptor binding in the basal ganglia

  2000cited by this paper
• Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice.

  2000cited by this paper
• Enhancement of Anandamide Formation in the Limbic Forebrain and Reduction of Endocannabinoid Contents in the Striatum of Δ9‐Tetrahydrocannabinol‐Tolerant Rats

  2000cited by this paper
• The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease.

  2000cited by this paper
• Fetal tissue transplants in animal models of Huntington's disease: the effects on damaged neuronal circuitry and behavioral deficits.

  2000cited by this paper
• Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide.

  1999cited by this paper
• Recent advances in understanding the pathogenesis of Huntington's disease.

  1999cited by this paper
• Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system.

  1998cited by this paper
• Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington's disease.

  1998cited by this paper
• Brain cannabinoid systems as targets for the therapy of neurological disorders.

  1998cited by this paper
• 3‐Nitropropionic acid's lethal triplet: cooperative pathways of neurodegeneration

  1998cited by this paper
• A novel effect of nicotine on mood and sleep in major depression

  1998cited by this paper
• Advances in Huntington's disease: implications for experimental therapeutics.

  1998cited by this paper
• Differential responses of extracellular GABA to intrastriatal perfusions of 3-nitropropionic acid and quinolinic acid in the rat.

  1997cited by this paper
• Huntington's disease.

  1997cited by this paper
• Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.

  1995cited by this paper
• Measurement of GABA in rat brain microdialysates using o-phthaldialdehyde-sulphite derivatization and high-performance liquid chromatography with electrochemical detection.

  1994cited by this paper
• Selective vulnerability in Huntington's disease: Preferential loss of cannabinoid receptors in lateral globus pallidus

  1994cited by this paper
• Loss of cannabinoid receptors in the substantia nigra in Huntington's disease.

  1993cited by this paper
• Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid

  1993cited by this paper
• Age‐Dependent Vulnerability of the Striatum to the Mitochondrial Toxin 3‐Nitropropionic Acid

  1993cited by this paper
• Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry.

  1992cited by this paper
• Neuronal localization of cannabinoid receptors in the basal ganglia of the rat.

  1991cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Unveiling the Potential of Phytocannabinoids: Exploring Marijuana’s Lesser-Known Constituents for Neurological Disorders

  2024cites this paper
• Interplay between the Glymphatic System and the Endocannabinoid System: Implications for Brain Health and Disease

  2023cites this paper
• Medicinal Cannabis and Central Nervous System Disorders

  2022cites this paper
• INVOLVEMENT OF THE ENDOCANNABINOID SYSTEM IN THE PATHOPHYSIOLOGY AND THERAPEUTICS OF MOVEMENT DISORDERS

  2022cites this paper
• Cannabinoid Receptors: An Update on Cell Signaling, Pathophysiological Roles and Therapeutic Opportunities in Neurological, Cardiovascular, and Inflammatory Diseases

  2020cites this paper
• Neuroprotective and Neurotoxic Effects of Endocannabinoid-like compounds, N-Arachidonoyl Dopamine and N-Docosahexaenoyl Dopamine in Differentiated Cultures of Induced Pluripotent Stem Cells Derived from Patients with Parkinson's Disease.

  2020cites this paper
• Cannabinoids Involvement in Neurodegenerative Diseases

  2019cites this paper
• Cannabinoids for Mental and Motor Dysfunctions in Neurodegenerative Diseases

  2018cites this paper
• Neuroprotection by Cannabinoids in Neurodegenerative Diseases

  2018cites this paper
• Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system

  2018cites this paper
• The Endocannabinoid System in Prefrontal Synaptopathies

  2017cites this paper
• Cannabinoid signaling in health and disease.

  2017cites this paper
• Endocannabinoid system in neurodegenerative disorders

  2017cites this paper
• URB597 reduces biochemical, behavioral and morphological alterations in two neurotoxic models in rats.

  2017cites this paper
• Global neuroprotection of huntingtin in culture and alterations of cortico-striatal connections in Huntington’s disease culture and mouse models

  2017cites this paper
• Neuroprotective effect of WIN55,212-2 against 3-nitropropionic acid-induced toxicity in the rat brain: involvement of CB1 and NMDA receptors.

  2017cites this paper
• The Endocannabinoid System and Human Brain Functions: Insight From Memory, Motor, and Mood Pathologies

  2017cites this paper
• The Endocannabinoid System in Local and Systemic Inflammation

  2017cites this paper
• From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology.

  2016cites this paper
• Cannabinoids and Motor Control of the Basal Ganglia: Therapeutic Potential in Movement Disorders

  2016cites this paper
• The bright side of psychoactive substances: cannabinoid-based drugs in motor diseases

  2016cites this paper
• Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy

  2016cites this paper
• The therapeutic potential of cannabinoids for movement disorders

  2015cites this paper
• Therapeutic implications of the endocannabinoid system in neurodegenerative diseases

  2015cites this paper
• Cannabinoids and Huntington’s disease

  2015cites this paper
• Discovery of the Endocannabinoid System: A Breakthrough in Neuroscience

  2014cites this paper
• Conclusions: Therapeutic Potential of Novel Cannabinoid Receptors

  2013cites this paper
• The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG

  2013cites this paper
• endoCANNABINOIDS

  2013cites this paper
• Cannabinoid receptors and neurodegenerative diseases

  2012cites this paper
• Functional interactions within striatal microcircuit in animal models of Huntington's disease.

  2012cites this paper
• [¹²⁵I]SD-7015 reveals fine modalities of CB₁ cannabinoid receptor density in the prefrontal cortex during progression of Alzheimer's disease.

  2012cites this paper
• Cannabinoid Modulation of Neuroinflammatory Disorders

  2012cites this paper
• Huntington’s Disease and Group I Metabotropic Glutamate Receptors

  2011cites this paper
• Synaptic Dysfunction in Huntington’s Disease

  2011cites this paper
• CBD & D9-THC - the two faces of cannabis

  2010cites this paper
• THEMED ISSUE: CANNABINOIDS REVIEW The endocannabinoid system as a target for the treatment of neurodegenerative disease

  2010cites this paper
• Cannabinoids and Dementia: A Review of Clinical and Preclinical Data

  2010cites this paper
• 3-Nitropropionic Acid as a Tool to Study the Mechanisms Involved in Huntington’s Disease: Past, Present and Future

  2010cites this paper
• Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders.

  2010cites this paper
• Quantification of brain endocannabinoid levels: methods, interpretations and pitfalls

  2010cites this paper
• Characterization of the CAG 140 Mouse Model of Huntington's Disease and the Effects of rAAV Delivered shRNA and hGFP

  2010cites this paper
• THEMED ISSUE: CANNABINOIDS REVIEW Quantification of brain endocannabinoid levels: methods, interpretations and pitfalls

  2010cites this paper
• The therapeutic potential of novel cannabinoid receptors.

  2009cites this paper
• Cannabinoid CB(1) receptor activation stimulates neurite outgrowth and inhibits capsaicin-induced Ca(2+) influx in an in vitro model of diabetic neuropathy.

  2009cites this paper
• Endocannabinoid system: emerging role from neurodevelopment to neurodegeneration.

  2009cites this paper
• The endocannabinoid system as a target for the treatment of motor dysfunction

  2009influential citation
• Biosynthesis of endocannabinoids and their modes of action in neurodegenerative diseases

  2009influential citation
• Adaptations of Striatal Endocannabinoid System During Stress

  2009cites this paper
• Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.

  2009cites this paper
• The Endocannabinoid System in the Physiology and Pathology of the Basal Ganglia

  2008cites this paper
• Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease.

  2008cites this paper
• The endocannabinoid system in Huntington's disease.

  2008cites this paper
• EXPRESSION OF BRAIN DERIVED NEUROTROPHIC ACTOR AND TYPE-1 CANNABINOID RECEPTOR AFTER STRIATAL

  2008cites this paper
• Cannabinoids and the brain

  2008cites this paper
• Overview of the chemical families of fatty acid amide hydrolase and monoacylglycerol lipase inhibitors.

  2008cites this paper
• The ins and outs of endocannabinoid signaling in healthy and diseased brain

  2008cites this paper
• IMMUNE SYSTEM MODULATION IN THE CENTRAL NERVOUS SYSTEM; A POSSIBLE ROLE FOR ENDOCANNABINOIDS

  2007cites this paper
• Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity.

  2007cites this paper
• Endocannabinoids and neurodegenerative diseases.

  2007cites this paper
• HETEROMERIZACIÓN DE RECEPTORES DE ADENOSINA A2A, DOPAMINA D2 Y CANNABINOIDES CB1. IMPLICACIONES FARMACOLÓGICAS Y FUNCIONALES.

  2007cites this paper
• Short- and long-term plasticity of the endocannabinoid system in neuropsychiatric and neurological disorders.

  2007cites this paper
• The endocannabinoid pathway in Huntington's disease: a comparison with other neurodegenerative diseases.

  2007cites this paper
• Plant, synthetic, and endogenous cannabinoids in medicine.

  2006cites this paper
• ETUDE DE L'AMPLIFICATION DE LA NEURODEGENERESCENCE EXCITOTOXIQUE PAR UNE DYSFONCTION MITOCHONDRIALE : IMPLICATIONS POUR LA MALADIE DE HUNTINGTON

  2006cites this paper
• Implication of Cannabinoids in Neurological Diseases

  2006cites this paper
• Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand.

  2006cites this paper
• Implication of Cannabinoids in Neurological Diseases

  2006cites this paper
• The Endocannabinoid System as an Emerging Target of Pharmacotherapy

  2006influential citation
• The biosynthesis, fate and pharmacological properties of endocannabinoids.

  2005cites this paper
• Cannabinoid control of motor function at the basal ganglia.

  2005cites this paper
• Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gamma-aminobutyric acid transmission in the striatum of R6/2 Huntington's disease mice.

  2005cites this paper
• Melatonin protects against neuronal damage induced by 3-nitropropionic acid in rat striatum.

  2005cites this paper
• 3‐Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease

  2005cites this paper
• Involvement of Cannabinoid Receptors in the Regulation of Neurotransmitter Release in the Rodent Striatum: A Combined Immunochemical and Pharmacological Analysis

  2005cites this paper
• Cannabinoids in neurodegeneration and neuroprotection

  2005cites this paper
• Behavioral Effects of Endocannabinoids

  2005cites this paper
• Occurrence, Biosynthesis, and Metabolism of Endocannabinoids

  2005cites this paper
• Endocannabinoids and Dopamine-Related Functions in the CNS

  2005cites this paper
• The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids

  2005cites this paper
• Molecular Involvement of Cannabinoid Receptors in the Regulation of Neurotransmitter Release in the Rodent Striatum : A Combined Immunochemical and Pharmacological Analysis

  2005cites this paper
• The endocannabinoid system and its therapeutic exploitation

  2004cites this paper
• Endocannabinoids and their involvement in the neurovascular system.

  2004cites this paper
• Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease

  2003influential citation
• The therapeutic potential of cannabis.

  2003cites this paper
• The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders

  2003cites this paper
• Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa‐induced dyskinesias

  2003cites this paper
• The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders.

  2003cites this paper
• Endocannabinoids and basal ganglia functionality.

  2002cites this paper
• Cannabinoid receptors and their ligands.

  2002cites this paper
• The Endocannabinoid Anandamide : Metabolism & Neuroprotection

  2002cites this paper
• The endogenous cannabinoid system and the basal ganglia. biochemical, pharmacological, and therapeutic aspects.

  2002cites this paper
• Loss of cannabinoid CB1 receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington’s disease

  2002cites this paper
• The therapeutic potential of the cannabinoids in neuroprotection

  2002cites this paper
• Acute neuronal injury, excitotoxicity, and the endocannabinoid system

  2002cites this paper
• Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease

  2002cites this paper
• Loss of cannabinoid CB(1) receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington's disease.

  2002cites this paper